The therapeutic efficacy of a 1-week course of treatment with YM155 (1 mg/kg per day), a 2-week course of treatment with IL-2 with an interval of 3 days (16000 U/mouse/3 times), and the combination of YM155 and IL-2 was evaluated by demonstration of decreased tumor volume, analyzed with anin vivo imaging and analysis (IVIS) instrument (Figure 3A and 3B), and lower weights of orthotopic renal and metastatic lung tumor tissues (Figure 4A and 4B, respectively). The gene discussed is IL2; the disease is neoplasm.